Barclays analyst Balaji Prasad maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) today and set a price target of $15.00. The company’s shares closed last Friday at $11.91.
Prasad covers the Healthcare sector, focusing on stocks such as Coherus Biosciences, Idexx Laboratories, and Dr Reddy’s Laboratories. According to TipRanks, Prasad has an average return of 2.2% and a 45.93% success rate on recommended stocks.
In addition to Barclays, Teva Pharmaceutical also received a Buy from UBS’s Ashwani Verma in a report issued on January 24. However, on January 25, J.P. Morgan assigned a Sell rating to Teva Pharmaceutical (NYSE: TEVA).
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $12.21 and a one-year low of $7.09. Currently, Teva Pharmaceutical has an average volume of 9.15M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Teva Pharmaceutical (TEVA) Company Description:
Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.
Read More on TEVA:
